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Stand der Wissenschaft und Technik bei der Notfall-Kontrazeption mit
innovativen Arzneimitteln
Abstract
The objective of this study is to evaluate and elucidated the potential
ofselectiveprogesteronereceptormodulators(SPRMs)tobeaneffective
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emergencycontraception(EC).Thedataareextractedfromtheliterature
through the MEDLINE database service from 2000–2010. 1 Department of Reproductive
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toprogesteronereceptor(PR)andexertantagonistic,agonisticormixed
Medical Sciences, Ansari
Nagar, New Dellhi, India
agonist-antagonistic effects. These SPRMs are mifepristone, onapris-
tone, asoprisnil, ulipristal, proellex among other compounds.
CurrentlydevelopedSPRMsmayexertcontraceptiveeffectsbyinhibiting
ovulation and retarding endometrial synchronization. Low-doses of
progesteroneantagonistsretardendometrialmaturationwithoutaffect-
ing ovulation. Mifepristone being a SPRM is effective for prevention of
pregnancybutwithprostaglandinactsasanexcellentabortifacient;yet
could not compete with levonorgestrel as EC. However, a single dose
of 30 mg ulipristal acetate, another SPRM with similar effectiveness
and side effect profiles as 1.5 mg levonorgestrel EC, has shown wider
‘window of effect’ by inhibition of the LH peak even if administered at
the advanced pre-ovulatory phase, a time when use of levonorgestrel
EC is no longer effective. Thus, ulipristal acetate goes one-step ahead
of levonorgestrel in the field of emergency contraception treatment.
Further studies are needed to explore the potential of other SPRMs to
be cutting edge emergency contraceptive drugs.
Keywords: receptor modulator, steroid ligands, ulipristal acetate, EC,
agonists, antagonists
Zusammenfassung
DasZielderStudieistes,dasPotentialderselektivenModulatorendes
Progesteronrezeptors (SPRM) zur wirksamen Notfall-Kontrazeption zu
evaluieren und darzustellen. Die Daten der Literatur sind mit Hilfe der
MEDLINE-Datenbank von 2000–2010 gesammelt worden.
Die Modulatoren des Progesteronrezeptors sind Liganden, die an den
Progesteronrezeptor binden und antagonistische, agonistische oder
gemischte agonistisch-antagonistische Effekte bewirken. SPRMs sind
u. a. Mifepristone, Onapristone, Asoprisnil, Ulipristal, Proellex.
DiederzeitentwickeltenSPRMsentfaltenihreWirkungdurchHemmung
der Ovulation und Verzögerung der endometrialen Synchronisation.
Niedrige Dosen von Progesteronantagonisten verzögern die endome-
triale Reifung, ohne die Ovulation zu beeinträchtigen. Mifepristone als
SPRM ist bei der Schwangerschaftsverhütung wirksam, aber mit Pros-
taglandinzusammenwirktesalsexzellentesAbortivum;esistallerdings
zurnotfallmäßigenEmpfängnisverhütungwenigerwirksamalsLevonor-
gestrel. Eine Einzelgabe vom 30 mg Ulipristalacetat, einem anderen
SPRM mit ähnlicher Wirksamkeit und Nebenwirkungen wie 1,5 mg Le-
vonorgestrel, hat ein breiteres Wirkungsspektrum durch Hemmung der
LH-Sekretion, selbst wenn es in der vorausgegangenen präovulatori-
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Introduction
The idea of mimicking the effect of progesterone in
blocking ovulation and thus inhibiting fertility was first
coined out by Gregory Pincus in 1950s. However, over
theyears,theoriginalmethodofhormonalcontraception
developed into a variety of modalities that today utilize
number of new routes of administration [1]. Curiosity
besides necessity is also a very potent factor that may
lead to discovery. Curious researches do not stop being
satisfied with the current state of emergency contracep-
tion(EC)withlevonorgestrel(LNG)onlycompoundthough
oraladministrationofasingledoseof1.5mgLNGisvery
effectiveandsafeforuseasECandisbeingusedinmany
countries for a long time. The search for the new EC regi-
men with LNG is still going on to find out more effective
systemforbetteruse-effectivenesswithnoadverseeffect
asasteptodevelopemergencycontraceptivedrugdeliv-
ery system that could also prevent sexually transmitted
infections as well. Thus, a vaginal gel levonorgestrel de-
livery system has recently been developed to use as EC
in reproductive health care for potential ‘dual protection’
from unintended pregnancy as well as sexually transmit-
ted infections (STIs)/AIDS [2]. However, levonorgestrel is
a synthetic steroid and an agonist to progesterone. At
present, scientific idea is pushing ahead to develop EC
withselectiveprogesteronereceptormodulators(SPRMs)
– the cutting edge drugs in the field of reproductive
medicine. In this review article, an endeavour has been
madetoevaluateandelucidatethepotentialoftheexist-
ing SPRMs to be used as an emergency contraceptive
drug.
Data extraction
DatawereextractedfromtheliteraturethroughMEDLINE
databaseserviceusingkeywords‘emergencycontracep-
tion’ and ‘progesterone receptor modulators’ from
2000–2010. Search outcome, the articles, surveys, re-
view, and clinical investigations relevant to the theme of
the article were included to build up this perspective re-
view.
Emergency contraception
What does it mean by emergency
contraception?
Emergency contraception (EC) may be defined as the
treatment received by or given to women for prevention
of pregnancy within 72 or 120 hours after unprotected
sexual intercourse. Levonorgestrel alone or in combina-
tionwithethinylestradiol,theYuzperegimen,andintrauter-
ine device (IUD)/copper IUD are the commonly used EC
available to women. Mifepristone is also used as EC in
China,CubaandThailand[3],[4],[5].TheFDAintheUSA
in August 2010 has approved ulipristal acetate as a pre-
scription drug for EC under the brand name, ‘ella’ for
prevention of pregnancy within 5 days after unprotected
sexualintercourseorcontraceptivefailure.Itisnotinten-
ded to use as routine contraceptive. However, ulipristal
acetate as a prescription product for EC has been avail-
able in European countries under the brand name,
‘ellaOne’ since 2009. Emergency contraception is avail-
ableinmorethan140countriesandthisisalsoavailable
over-the-counter without clinician’s prescription in about
50 countries [6].
Drug, doses and devices
A single dose of 1.5 mg LNG pill in various local brand
names is presently available over-the-counter (OTC) in
many countries, e.g. Plan B/Plan B One step in the USA,
Levonelle/LevonelleOnestepintheUKandi-pillinIndia.
The 0.75 mg LNG two pills regimen known as E-pills is
alsoavailabletoIndianwomenfreeofcostfromthestate
health service outlets. The single dose EC pill is to be
takenbywomenwithin72or120hoursafterunprotected
sexual intercourse. Two 0.75 mg LNG pills may be taken
together as a single dose or either 12 or 24 hours apart
within 72 or 120 hours after unprotected intercourse
because of similar effect [7], [8] .
In an attempt to incorporate LNG emergency contracep-
tive drug to a delivery system that could also discharge
anactivecompound(apotentmicrobicide)againstmicro-
organisms, the Carraguard vaginal gel (4 ml) containing
0.75 mg or 1.5 mg LNG has been developed for dual
protection against conception and STI/AIDS [2].
Among the selective progesterone receptor modulators,
mifepristone and ulipristal acetate are being used as EC.
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acetateisusedasECwithin72or120hoursafterunpro-
tected sexual intercourse to prevent unintended preg-
nancy.
The IUDs/copper IUDs can be inserted as EC within
120 hours after unprotected intercourse and are very
effective to prevent pregnancy. Women are offered IUD
as in usual clinical practice if they presented >72 hours
after unprotected sexual intercourse. However, an IUD
would provide a regular method of contraception.
Selective progesterone receptor
modulators
What are selective progesterone
receptor modulators?
Theselectiveprogesteronereceptormodulators(SPRMs)
are progesterone receptor ligands that could bind with
progesterone receptors and exert antagonistic, agonistic
ormixedagonistic-antagonisticeffectsdependingonthe
cellular context of the target tissues [9], [10]. Among
several hundred, nearly a dozen of SPRMs have been
evaluated to any significant extent. The best known
SPRMs are mifepristone, asoprisnil, onapristone, uli-
pristal, and proellex [11].
Currently developed SPRMs are derivatives of steroid
compounds with mild or potent anti-progestogen activity.
SPRMs may exert a contraceptive activity by different
mechanismssuchasinhibitionofovulationanddisruption
of endometrial synchronization. Their potential clinical
applications are manifold and very promising in major
public health areas, including emergency contraception,
longtermestrogen-freecontraceptionadministeredalone
or in association with a progestogen-only pill to improve
bleeding patterns. In future clinical application, SPRMs
may be administered through the oral, intra-uterine or
vaginal route [12].
How does progesterone receptor work?
Progesterone receptor (PR) contains well defined func-
tional domains: the N-terminal transcription domain, the
central DNA binding domain, the hinge region and the
C-terminal hormone binding domain. The binding of pro-
gesterone or antagonist such as mifepristone produces
conformational changes in the form of PR that permits it
to bind to DNA of the target cells. Human PR has two
isoforms, PR-A and PR-B that form homo and/or hetero
dimmers in the transcription activation process. The ac-
tivated receptor dimmers (AA, BB, or AB) bind to proges-
terone response elements in the promoter region of pro-
gesterone gene [13].
In the case of progesterone, this binding increases the
transcription of these genes producing progesterone ef-
fects.Incontrast,areceptordimercomplexthathasbeen
activated by mifepristone also binds to progesterone re-
sponse elements, but an inhibitory function in the C-ter-
minal region of hormone binding domain renders this
DNA bound receptor transcription inactive. This is the
basisoftheprogesteroneantagonisticactionofmifepris-
tone or other SPRMs underlying their abortifacient and
contraceptive actions [13].
How do SPRMs work?
In the field of contraception, SPRMs have shown contra-
ceptive potential by suppressing follicular development,
delaying surge of luteinizing hormone (LH), retarding en-
dometrial maturation and promoting endometrial bleed-
ing. Mifepristone, a best known SPRM, showed a strong
interceptingaction.Studiessuggestedthattheendomet-
riumwasmoresusceptibletomifepristonethanwerethe
hypothalamus and pituitary regions [14], [15]. Shortly
after LH surge, treatment with mifepristone affected the
secretaryapparatusandpolarityoftheendometrialcells
in women. Administration of mifepristone in early luteal
phase disrupted the secretory activity of endometrial
glandularcells.Thisfindingsuggestedacellularmechan-
ism of progesterone receptor (PR) blockage by mifepris-
tone in the peri-implantation period [16]. Mifepristone at
alowdoseresultedinabnormalendometrialmorphology
inwomen.Theendometrialglandsexhibitedirregularities
inshapeandsizeandwerelinedbymixedepithelialcells
some of which were secretory. The concentration of es-
trogen receptor (ER) was greater in the stroma with no
difference in PR compared with the control, whereas no
change in ER or PR concentration was observed in endo-
metrial glands. Thus, low dose of mifepristone seems to
antagonizeprogesteroneinducedsecretorychangesthat
are necessary for the implantation [17], [18].
Mifepristone, in daily doses of 2–10 mg blocks the LH
surge and ovulation. There is evidence that daily doses
of 2 or 5 mg mifepristone have contraceptive potential.
Because of anovulation, there may be an unopposed ef-
fect of estrogen on the endometrium, although this risk
may be mitigated by the noncompetitive anti-estrogenic
activity exhibited by SPRMs. Low doses of SPRMs retard
endometrial maturation, without affecting ovulation,
thereby indicating that the endometrium is exquisitely
sensitive to these compounds. Here is the prospect for
the development of endometrial contraception. This
means that contraception could be achieved with these
compounds by prevention of endometrial maturation
without disturbing ovulation or producing alteration in
bleeding patters [19].
Though200mgmifepristoneasaneffectivecontraceptive
drugadministered48hoursafterLHsurgedoesnotaffect
ovulation or bleeding pattern, yet it is not a popularly ac-
ceptableapproachforcontraception.Mifepristoneadmin-
istered at late luteal phase either alone or together with
prostaglandins produces menstrual bleeding and is not
very effective for prevention of pregnancy. However,
treatment with mifepristone-prostaglandin combination
is very effective for occasional menstrual regulation, in-
duction of vaginal bleeding in 98% of pregnant women,
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couldalsobeusedasaneffectiveemergencycontracept-
ive agent [13]; but because of delay in onset of next
menstrualcyclethatissignificantlydoserelated,mifepris-
tone could not compete with levonorgestrel compound
for EC [20]. Mifepristone is widely used to terminate
pregnancyandassuchiscommerciallyavailableinmany
countries. The negative abortion-related image of mife-
pristone has clearly limited the involvement of major
pharmaceutical companies in the development of mife-
pristone as well as other SPRMs as contraceptive drugs
[21].
Many SPRMs displayed direct anti-proliferative effects
ontheendometrium,althoughwithvariableactionswhich
seemedtobeproduct-anddose-dependent.Progesterone
antagonists suppressed late follicular development,
blocked the LH surge and retarded endometrial matura-
tion,whichrenderedthempotentialestrogen-freecontra-
ceptive drugs. However, a SPRM such as asoprisnil was
not so effective as to block the LH surge but appeared
to target the endometrium directly and produced amen-
orrhoea.Treatmentwiththesecompoundswasnotasso-
ciatedwithhypo-estrogenismandboneloss.Thepotential
clinical application of these compounds covered a broad
fieldandwasverypromisinginmajorpublichealthareas
such as emergency contraception, long-term estrogen-
free contraception, myoma and endometriosis [20].
However, the data from mid- to long-term continuous
administrationstudieshaveraisedtheissueofendometri-
al safety. In consequence, long-term applications of
SPRMs are currently postponed [9].
Investigation and clinical trials
TheSPRMsareaclassofdrugswithprogesteroneantag-
onist activity that may confer therapeutic benefit for re-
productive disorders in postmenopausal women. The
endometrial structure of those women is likely to be per-
turbed by SPRMs through their progesterone antagonist
properties. The histological findings after treatment for
endometriosis with proellex showed generally inactive or
atrophic endometrium and less frequently, proliferative
or secretary, and superimposed upon changes including
formation of cystically dilated glands. The secretory
changes coexisted with mitoses and apoptotic bodies,
with increasing treatment, dose and duration. None of
the proellex treated patients developed endometrial car-
cinoma or hyperplasia while on therapy [22]. Pharmaco-
logically, ulipristal acetate is a synthetic steroid that has
demonstrated potent progesterone antagonist activity in
vitro and in vivo. As compared to mifepristone, this com-
pound has reduced anti-glucocorticoid activity, inhibited
ovulation in rats in a dose dependent manner and exhib-
itedanti-fertilityactivityduringcontinuousadministration.
Because of unique pharmacological profile, ulipristal
acetate seemed to be a promising candidate for use as
contraceptive drug [23]. Therefore further studies are
required to explore the use-effective functions of these
cuttingedgecompoundsinthefieldofreproductivehealth
care.
Use as emergency contraception
Mifepristone
Mifepristone is well recognized as an abortifacient but in
a low dose, it is still used as EC in a few countries. In
Cuba, effectiveness of 10 mg mifepristone for EC up to
5 days after unprotected intercourse in 635 women was
evaluated. The pregnancy was prevented in 88% cases
andtheratewas1.1%.Fatigue(10.7%),dizziness(6.1%),
nausea (4.9%), and vomiting (0.6%) were common ad-
verse effects reported by women. Menstruation was
delayed more than 7 days in 6% women [4]. Thai women
also used 10 mg mifepristone for EC within 120 hours
after unprotected sexual intercourse. No pregnancy oc-
curred among them. The interval and duration of the
treatmentcyclesweresignificantlylongerthanuntreated
controlled cycles [5]. A comparative clinical trial in China
showed that the treatment with 10 mg mifepristone in
499 women up to 72 hours after unprotected sexual in-
tercourse resulted in 1.8% pregnancy rate as compare
to 2.4% with 10 mg gestrinone for EC. Majority of women
menstruatedinthefirstdayoftheexpectedmenses.Two
treated groups did not differ significantly regarding the
adverse effects of the treatment. The effectiveness of
10 mg gestrinone was not significantly different from
thoseof10mgmifepristoneasanemergencycontracept-
ive drug [3].
Mifepristoneat25–50mgwassuperiortootherhormonal
regimens;butatlowdose,itcouldbemoreeffectivethan
LNG, 0.75 mg two doses. A single dose of 1.5 mg LNG
seemed to have similar effectiveness as the standard
0.75 mg two doses at 12 hours apart. LNG was more ef-
fectivethanYuzperegimen.Therewasmorepregnancies
with LNG as compared to 25–50 mg or <25 mg mifepris-
tone. Ulipristal acetate seemed to be as effective as LNG
but the confidence interval was wide and the result
compatible with higher or lower effectiveness [24]. The
pregnancies rates were 1.5% in women given 10 mg
mifepristone, 1.5% in those assigned a single 1.5 mg
dose of LNG, and 1.8% in women assigned 0.75 mg two
doses of LNG. These rates were not statistically signific-
ant. The relative risk of pregnancy for 1.5 mg LNG com-
paredwithtwodosesLNGwas0.83andthatfor0.75mg
two doses LNG compared with 10 mg mifepristone was
1.05. The adverse effects were mild and did not differ
greatly between groups. The most women menstruated
within two days of the expected date; women who took
LNG had earlier menstruation than did those who took
mifepristone. These regimens of EC were very effective
to prevent high proportion of pregnancies if taken within
five days of unprotected sexual intercourse. Mifepristone
andLNGdidnotdifferinefficacy.Asingledoseof1.5mg
LNG could substitute two doses of 0.75 mg taken at 12
hours apart [25].
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Inacomparativeclinicaltrialwith50mgulipristalacetate
versus two doses of 0.75 mg LNG, the pregnancy rate
was 0.9% and 1.7%, respectively. About 85% and 69%
ofanticipatedpregnancywereaverted,respectivelybased
on the estimated cycle day of unprotected sexual inter-
course. Nausea was experienced by more women (29%)
ofulipristalgroupthanwomen(24%)ofLNGgroup.Thus,
ulipristal acetate was as effective as LNG in preventing
pregnancyafterunprotectedsexualintercourseandboth
drugs had similar side effect profiles [26].
In a study in Texas, USA, the efficacy and safety of uli-
pristalacetateforECwasevaluated.Womenweretreated
with 30 mg ulipristal acetate within 48 to120 hours after
unprotectedintercourse.Thepregnancyrateswere2.3%,
2.1%,and1.3%fortreatmentintervalsof48to72hours,
>72 to 96 hours and >96 to 120 hours, respectively.
Adverse effects were mild or moderate, mostly being
headache, nausea and abdominal pain. Duration of
menstrual bleeding did not change but cycle length in-
creased by 2.8 days. Ulipristal acetate EC was effective
and well tolerated by women [27].
The multicentre study in Europe and the USA compared
the efficacy and safety of 30 mg ulipristal acetate with
that of 1.5 mg levonorgestrel for EC in 1,696 women, on
administering within 72 hours after unprotected inter-
course. The pregnancy rate was 1.8% and 2.6% with uli-
pristal acetate and LNG, respectively. However, 103 wo-
menwhoreceivedECbetween72to120hourshadthree
pregnanciesallinLNGgroup.Theheadachewasthemost
frequentadverseeffectamongusersofulipristalacetate
(19.3%) and LNG (18.9%). Ulipristal acetate could be
used for EC up to 5 days after unprotected sexual inter-
course [6].
The current methods of hormonal EC are ineffective to
prevent rupture of follicle when taken at the advanced
preovulatory phase. However, follicular rupture failed to
occur during the 5 day period in 44%, 50%, and 36% of
the cycles in women treated with 1.5 mg, 0.75 mg LNG
and placebo, respectively. Ovulatory dysfunction charac-
terized by follicular rupture associated with absent,
blunted or mistimed gonadotrophin surge occurred in
35%, 36%, and 5% of 1.5 mg, 0.75 mg LNG or placebo
cycles,respectively.Thus,LNGcoulddisrupttheovulatory
process in 93% of cycles treated when the diameter of
the dominant follicle was between 12 and 17 mm. Most
probably,thismodeofactionaccountsforthecontracept-
ive effectiveness and failure rate of levonorgestrel as EC
[28].
Does ulipristal acetate block follicular rupture when ad-
ministered at the preovulatory phase with a follicle
≥18 mm diameter? The study showed that follicular rup-
turefailedtooccurover5daysfollowingulipristalacetate
intake in 59% of women. When this drug was taken by
women before onset of the LH surge, or after onset of
the LH surge but before the LH peak, the ovarian follicles
failed to rupture for at least 5 days in 100% or 78.6% of
cycles, respectively. When ulipristal acetate was admin-
istered after LH peak, failure of follicular rupture was
noticedonlyin8.3%cycles.Thus,ulipristalacetatecould
delayfollicularruptureiftakenimmediatelybeforeovula-
tion. This SPRM as EC could perhaps prevent pregnancy
when given in advanced follicular phase at the onset of
LH surge, a time when LNG EC is no longer effective in
inhibiting ovulation [29].
The main mechanism of action of both LNG EC and uli-
pristal acetate EC is delay in, or inhibition of ovulation.
The ‘window of effect’ for LNG EC appears to be rather
narrow–itbeginsaftertheselectionofdominatingfollicle
and ends at the beginning of the rise of LH surge –
whereas, ulipristal acetate seems to cause suppression
of the preovulatory LH peak, as envisaged by Brache et
al. [29], that boosts its effectiveness further even when
administeredshortlybeforeovulation,thetimewhenuse
of LNG EC is no longer effective. Thus, ulipristal acetate
seemstohavehigherefficacyforECascomparedtoLNG
ECandbeinganewtypeofsecondgenerationprogester-
one receptor modulator, represents a new evolutionary
step in EC treatment [30].
Conclusions
With great potential of selective progesterone receptor
modulators to be a drug of choice in the various fields of
reproductive health care, it is not impossible to have
state-of-the-art of emergency contraception with cutting
edge SPRMs in near future. Though 1.5 mg single dose
or 0.75 mg double doses of LNG at 12 hours apart is
currently gold standard regimen for EC, the 30 mg uli-
pristal acetate with its functional and safety profiles
similar to that of LNG EC goes one-step ahead of LNG
because of its increased window of effect by inhibition of
the LH peak even when administered shortly before
ovulation, a time when LNG is no longer effective. This
advantage seems to stamp out ulipristal acetate as su-
perior to LNG for EC; further studies may confirm this
view in near future.
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